Background
==========

The discovery that mammalian cells grown in the presence of inhibitors of mitochondrial DNA (mtDNA) replication and transcription can lose all or almost all their mtDNA has provided a powerful means to study interactions between the mitochondrial and nuclear genomes, reviewed in \[[@B1]-[@B4]\]. The human mitochondrial genome is 16,569-bp in length and encodes 12S and 16S rRNAs, 22 tRNAs, and 13 polypeptides involved in the respiratory electron transport chain and ATP synthesis. The comprehensive MitoP2 database of human mitochondrial proteins <http://www.mitop.de:8080/mitop2/showhumanmask.do> lists 870 human mitochondrial proteins encoded by the nuclear genome \[[@B5]\]. Proteomic and systems biology approaches will likely unearth additional proteins directly involved in human mitochondrial function \[[@B6]\]. However, fundamental questions will remain about the influences mtDNA has on the regulation of nuclear genes *in vivo*.

mtDNA-depleted ρ^0^cell lines are auxotrophic for pyruvate and uridine, and are incapable of aerobic respiration due to the lack of key respiratory chain components \[[@B7],[@B8]\]. Nonetheless, mtDNA-depleted cell lines possess distorted mitochondria-like structures comprised of nuclear-encoded mitochondrial proteins \[[@B9]-[@B11]\] and demonstrate increased invasive behavior in culture \[[@B12]-[@B17]\] Furthermore, mtDNA-depleted cells can grow as tumor xenografts in immune-deficient mice in some instances \[[@B18],[@B19]\], but not others \[[@B20]\].

Here, we generated mtDNA-depleted A549 ρ^0^lung cancer cells and validated their genetic and biochemical properties in culture and tumor xenografts. Our gene expression profiling analyses of parental A549 and A549 ρ^0^cells uncovered differential expression of transcripts relevant to immune recognition, autophagy of defective mitochondria, HIF-mediated gene regulation, the epithelial-mesenchymal transition (EMT), and elimination of lipophilic molecules. Furthermore, growth in culture versus in xenograft had a greater effect on the A549 transcriptome, especially nuclear-encoded genes important for mitochondrial function and energy metabolism, than the presence of mtDNA. Overall, mtDNA-depleted cells grown in culture and in xenograft provide complementary means to identify relationships between mitochondrial activity and cellular gene expression profiles that could serve as potential biomarkers of disease.

Methods
=======

Cells and cell culture reagents
-------------------------------

A549 lung cancer cells were obtained from the American Type Culture Collection. Unless otherwise indicated, all cell culture reagents were purchased from Invitrogen. mtDNA-deficient A549 ρ^0^cell cultures were prepared by serial passage of parental A549 cells for 28 population doublings in standard growth media (RPMI 1640 medium supplemented with 20 mM HEPES, 2 mM L-glutamine, 10% heat inactivated fetal bovine serum (Hyclone), 200 U/mL penicillin, and 200 μg/mL streptomycin) in the presence of ethidium bromide (100 ng/mL), sodium pyruvate (1 mM), and uridine (50 μg/mL). The glucose concentration in the standard growth media is approximately 11 mM. All subsequent experiments employing A549 and A549 ρ^0^cell cultures were conducted in the same standard growth media supplemented only with sodium pyruvate (1 mM) and uridine (50 μg/mL). Growth curves were obtained by Coulter counting. All experiments were conducted using cell culture populations and not purified clones.

Estimation of mtDNA levels
--------------------------

mtDNA levels in A549 or A549 ρ^0^cell cultures were estimated using the pseudogene ratioing method \[[@B21]\]. Briefly, total DNA (both mitochondrial and genomic) was extracted from A549 or A549 ρ^0^cell cultures using the QIAamp DNA Mini Kit (Qiagen). These served as templates for PCR amplification using primers designed to anneal either to mtDNA or a previously described DNA-embedded mtDNA pseudogene (mtDNAψ) \[[@B22]\]. Amplicons derived from either nuclear DNA-embedded mtDNA pseudogene or mtDNA templates are predicted to be approximately the same length, but differ in sequence. These amplicons served as templates for a nested PCR using primers designed to amplify both the mtDNA-encoded *MT-CO2*and the nuclear DNA-embedded mtDNAψ sequences. The resulting amplicons were subcloned using the StrataClone™ PCR cloning system (Stratagene). Plasmid DNA from individual colonies was prepared for sequencing using the illustra TempliPhi 100/500 DNA Amplification Kit (GE Healthcare). The resulting products were sequenced using BigDye Terminator v3.0 from Applied Biosystems diluted with halfBD (Genetix Ltd.), according to manufacturer\'s recommendations. We obtained sequence information from 70 colonies derived from A549 DNA templates (all showed mtDNA sequences) and 92 colonies derived from A549 ρ^0^DNA templates (all showed mtDNAψ sequences). mtDNA abundance in the original A549 or A549 ρ^0^DNA preparation was estimated based on the number of colonies showing mtDNA or mtDNAψ sequences, as previously described \[[@B21]\].

Oxygen consumption
------------------

Oxygen consumption rates were measured using a Clark-type electrode \[[@B23]\]. In brief, plateau phase cultures of A549 or A549 ρ^0^cells were treated with antimycin A (1 μg/mL) or control vehicle for 3 hours. After medium was removed, cells were washed with Hanks balanced salt solution (HBSS), and harvested using trypsin/EDTA. Cells were resuspended in complete medium, stored on ice, and aliquots were removed for Coulter counting and viability (defined as ability to exclude propidium iodide). Prior to measurement, an aliquot of cell suspension (ca. 1 × 10^7^cells/mL) was incubated at 37°C for 2 minutes, and then transferred to the sealed electrode chamber of an Oxytherm apparatus (Hansatech, Norfolk, UK) to measure dissolved oxygen concentration. Background oxygen consumption by the electrode in the absence of cells was subtracted from all measurements.

Quantitative RT-PCR analysis
----------------------------

RNA was obtained from cultured A549 cells or harvested from tumor specimens as described \[[@B24]\]. Total RNA was quantified using the Ribogreen RNA quantitation kit (Molecular Probes). One-step RT-PCR assays were set up in triplicate according to manufacturer\'s instructions using the Taqman master mix (Applied Biosystems, Inc.) and 50 ng of total RNA as template. The amount of RNA in each well was re-quantified and used for normalizations. Gene expression assay probe sets for *β-actin*, *MT-ATP6*, and *MT-CYB*were purchased from Applied Biosystems and assays were performed on an ABI PRISM 7300 instrument according to standard protocols.

ELISA and Western blotting
--------------------------

Total HIF-1a protein was detected by sandwich ELISA using the DuoSet IC™ HIF-1a ELISA kit obtained from R&D Systems. Briefly, 96-well plates were coated with HIF-1a capture antibody overnight prior to blocking with 5% BSA in wash buffer. Protein lysates (50 μg protein per well prepared according to the manufacturer\'s instructions) were added for 2 hours, whereupon plates were washed and a biotinylated detection antibody specific for HIF-1a was added. A streptavidin-horseradish peroxidase format was used for detection. The optical density at 450 minus 570 nm was measured using a microplate reader (SpectraMax Plus). HIF-1a concentrations were calculated by linear regression using a standard curve prepared from HIF-1a standard supplied with the ELISA kit.

Western blotting was performed using antibodies against GLUT1 (aka SLC2A1, rabbit polyclonal), PGK1 (goat polyclonal), MTCO2 (mouse monoclonal), PDK1 (rabbit polyclonal), and DDIT4 (rabbit polyclonal) obtained from Santa Cruz Biotechnology, Molecular Probes, Stressgen, and Proteintech, respectively. All membranes were blotted with an anti-Hsc70 (mouse monoclonal, Santa Cruz Biotechnology) antibody to control for loading and transfer. HRP-conjugated goat anti-rabbit and goat anti-mouse secondary antibodies were from Pierce. HRP-conjugated donkey anti-goat secondary antibody was from Santa Cruz Biotechnology. HRP substrate was from Pierce. Bands were imaged and quantified in the linear range and normalized to Hsc70, using the ChemiDoc XRS Imaging System (BioRad Laboratories, Inc.).

Gene expression profiling in cell culture
-----------------------------------------

A549 or A549 ρ^0^human lung cancer cells (1 × 10^5^cells per T-25 flask in 7 mL complete RPMI 1640 medium) were seeded 8 days prior to RNA isolation. Each experiment was performed in triplicate. After incubation, all cultures were washed twice with HBSS supplemented with 0.5% BSA and total RNA was isolated and subjected to analysis on Human Genome U133A Arrays (Affymetrix), as described \[[@B24],[@B25]\]. ArrayAssist software (Stratagene) was used to generate scaled log2 transformed gene expression scores based on the RMA algorithm and to conduct hierarchical clustering analyses, as previously described \[[@B24]\]. Probe sets with a \> 1.5-fold differential expression (two-tailed Student\'s t-test *P*\< 0.01 subjected to Benjamini and Hochberg correction for multiple comparisons, and \> 20 unit difference in the geometric mean expression scores) in a comparison of interest are reported.

We used analysis of variance to estimate the proportion of variance explained by mtDNA status and explained by growth conditions, in the gene expression profiles from A549 ρ^0^and parental A549 cells grown in culture and in xenografts. Statistical significance is determined using the Bayes Moderated F test \[[@B26]\] implemented using the limma package in Bioconductor \[[@B27]\]. This uses an empirical Bayes approach, providing more stable inference when the number of arrays is small. *P*-values are adjusted for multiple comparisons using the Benjamini and Hochberg approach to control the false-discovery rate \[[@B28]\].

GeneOntology and KEGG analyses were conducted using WebGestalt software <http://bioinfo.vanderbilt.edu/webgestalt/>\[[@B29]-[@B31]\]. All scaled fluorescent intensity values and .cel files are available at the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) repository <http://www.ncbi.nlm.nih.gov/geo/> under Series Accession Number GSE10957. In addition, all scaled fluorescent intensity values are available in Supplemental Table [1](#T1){ref-type="table"}.

###### 

Transcripts where 90% of the variance in gene expression is explained by mtDNA status

                                    Affymetrix Probe ID   Gene Symbol   Entrez GeneID   Gene Description                           ρ^0^Proportion of Variance^a^   F test^b^        ρ^0^Vitro/A549 Vitro   ρ^0^Vivo/A549 Vivo           
  --------------------------------- --------------------- ------------- --------------- ------------------------------------------ ------------------------------- ---------------- ---------------------- -------------------- ------- --------
  **Up-regulated in ρ^0^cells**     214247_s\_at          *DKK3*        27122           dickkopf homolog 3                         0.98                            8.62 × 10^-11^   4.4                    0.0009               3.7     0.0005
                                    209822_s\_at          *VLDLR*       7436            very low density lipoprotein receptor      0.98                            7.05 × 10^-10^   3.3                    0.0057               2.7     0.0002
                                    210105_s\_at          *FYN*         2534            FYN oncogene                               0.97                            9.85 × 10^-9^    3.4                    0.0082               2.7     0.0009
                                    221305_s\_at          *UGT1A8*      54576           UDP glucuronosyltransferase 1 family       0.97                            1.21 × 10^-8^    8.3                    0.0088               13.1    0.0007
                                    202242_at             *TSPAN7*      7102            tetraspanin 7                              0.96                            3.45 × 10^-11^   9.3                    0.0046               9.3     0.0005
                                    205119_s\_at          *FPR1*        2357            formyl peptide receptor 1                  0.96                            3.82 × 10^-9^    3.8                    0.0045               4.8     0.0010
                                    208596_s\_at          *UGT1A10*     54575           UDP glucuronosyltransferase 1 family       0.96                            1.20 × 10^-10^   6.2                    0.0051               10.2    0.0001
                                    219093_at             *PID1*        55022           hypothetical protein FLJ20701              0.95                            1.41 × 10^-8^    5.4                    0.0090               4.2     0.0020
                                    209040_s\_at          *PSMB8*       5696            proteasome subunit                         0.95                            2.73 × 10^-10^   3.2                    0.0048               2.9     0.0003
                                    206094_x\_at          *UGT1A6*      54578           UDP glucuronosyltransferase 1 family       0.95                            6.79 × 10^-11^   5.9                    0.0041               9.7     0.0001
                                    219959_at             *PTHLH*       55034           parathyroid hormone-like hormone           0.94                            2.77 × 10^-9^    2.8                    0.0079               3.1     0.0005
                                    201042_at             *TGM2*        7052            transglutaminase 2                         0.94                            1.64 × 10^-6^    1.6                    0.0245               1.6     0.0014
                                    207126_x\_at          *UGT1A4*      54657           UDP glucuronosyltransferase 1 family       0.93                            3.45 × 10^-11^   6.7                    0.0048               11.5    0.0000
                                    203113_s\_at          *EEF1D*       1936            eukaryotic translation elongation factor   0.92                            1.10 × 10^-5^    1.5                    0.0291               1.6     0.0042
                                    204802_at             *RRAD*        6236            Ras-related associated with diabetes       0.92                            9.09 × 10^-7^    2.5                    0.0289               2.7     0.0044
                                    215125_s\_at          *UGT1A10*     54575           UDP glucuronosyltransferase 1 family       0.92                            8.62 × 10^-11^   7.2                    0.0045               12.7    0.0001
                                    213587_s\_at          *ATP6V0E2*    155066          ATPase, H+ transporting V0 subunit e2      0.92                            3.60 × 10^-6^    1.7                    0.0447               1.9     0.0021
                                    217739_s\_at          *PBEF1*       10135           pre-B-cell colony enhancing factor 1       0.91                            4.54 × 10^-7^    3.8                    0.0141               11.0    0.0004
                                    204532_x\_at          *UGT1A4*      54657           UDP glucuronosyltransferase 1 family       0.91                            3.96 × 10^-10^   5.8                    0.0055               10.9    0.0000
                                    212160_at             *XPOT*        11260           exportin, tRNA                             0.91                            1.52 × 10^-5^    1.6                    0.0524               1.9     0.0015
                                    212307_s\_at          *OGT*         8473            GlcNAc transferase                         0.91                            6.52 × 10^-7^    1.7                    0.0273               2.4     0.0007
                                    203262_s\_at          *FAM50A*      9130            family with sequence similarity 50         0.91                            3.01 × 10^-5^    1.5                    0.0435               1.6     0.0030
                                    217738_at             *PBEF1*       10135           pre-B-cell colony enhancing factor 1       0.91                            1.76 × 10^-7^    4.5                    0.0054               11.2    0.0007
                                    201462_at             *SCRN1*       9805            secernin 1                                 0.90                            2.79 × 10^-5^    1.4                    0.0186               1.5     0.0032
                                    219762_s\_at          *RPL36*       25873           ribosomal protein L36                      0.90                            8.04 × 10^-6^    1.4                    0.0073               1.7     0.0014
                                    212909_at             *LYPD1*       116372          LY6/PLAUR domain containing 1              0.90                            1.04 × 10^-5^    2.5                    0.0069               1.7     0.0050
                                    215025_at             *NTRK3*       4916            neurotrophic tyrosine kinase, receptor     0.90                            6.53 × 10^-7^    2.6                    0.0179               2.2     0.0048
                                    201474_s\_at          *ITGA3*       3675            integrin, alpha 3                          0.90                            1.57 × 10^-6^    1.8                    0.0491               1.8     0.0018
  **Down-regulated in ρ^0^cells**   211600_at             *MT-ND5*      4540            mito. encoded NADH dehydrogenase 5         0.99                            4.48 × 10^-14^   -73.7                  0.0007               -46.9   0.0001
                                    205674_x\_at          *FXYD2*       486             FXYD domain ion transport regulator 2      0.98                            3.45 × 10^-11^   -11.0                  0.0029               -14.8   0.0004
                                    211203_s\_at          *CNTN1*       1272            contactin 1                                0.97                            4.65 × 10^-9^    -4.7                   0.0009               -3.6    0.0015
                                    204698_at             *ISG20*       3669            interferon stimulated exonuclease gene     0.96                            3.67 × 10^-8^    -3.5                   0.0056               -2.9    0.0014
                                    210065_s\_at          *UPK1B*       7348            uroplakin 1B                               0.95                            4.17 × 10^-8^    -4.3                   0.0071               -6.2    0.0013
                                    203108_at             *GPRC5A*      9052            G protein-coupled receptor                 0.95                            4.96 × 10^-9^    -3.4                   0.0048               -5.9    0.0001
                                    207434_s\_at          *FXYD2*       4151            FXYD domain ion transport regulator 2      0.95                            2.29 × 10^-11^   -9.8                   0.0063               -12.9   0.0003
                                    201065_s\_at          *GTF2I*       2969            general transcription factor II, i         0.95                            6.30 × 10^-7^    -2.0                   0.0109               -1.7    0.0010
                                    210064_s\_at          *UPK1B*       7348            uroplakin 1B                               0.95                            1.51 × 10^-8^    -5.8                   0.0081               -5.9    0.0020
                                    222088_s\_at          *SLC2A3*      6515            solute carrier family 2, member 3          0.95                            1.46 × 10^-8^    -2.1                   0.0080               -2.4    0.0010
                                    33304_at              *ISG20*       3669            interferon stimulated exonuclease gene     0.95                            3.70 × 10^-7^    -2.9                   0.0077               -2.4    0.0036
                                    218995_s\_at          *EDN1*        1906            endothelin 1                               0.94                            3.16 × 10^-7^    -2.2                   0.0333               -2.7    0.0014
                                    219045_at             *RHOF*        54509           ras homolog gene family, member F          0.93                            4.81 × 10^-7^    -2.9                   0.0062               -2.0    0.0018
                                    214774_x\_at          *TNRC9*       27324           trinucleotide repeat containing 9          0.93                            4.39 × 10^-7^    -2.9                   0.0109               -3.9    0.0027
                                    206291_at             *NTS*         4922            neurotensin                                0.93                            6.81 × 10^-8^    -102                   0.0009               -17.9   0.0011
                                    201909_at             *RPS4Y1*      6192            ribosomal protein S4, Y-linked 1           0.92                            3.55 × 10^-8^    -5.8                   0.0071               -18.8   0.0000
                                    206700_s\_at          *JARID1D*     8284            jumonji, AT rich interactive domain 1D     0.90                            2.41 × 10^-7^    -2.3                   0.0366               -4.0    0.0000
                                    203043_at             *ZBED1*       9189            zinc finger, BED-type containing 1         0.90                            6.01 × 10^-6^    -1.7                   0.0427               -1.9    0.0026
                                    202499_s\_at          *SLC2A3*      6515            solute carrier family 2, member 3          0.90                            2.86 × 10^-6^    -1.9                   0.0128               -2.3    0.0073
                                    216623_x\_at          *TNRC9*       27324           trinucleotide repeat containing 9          0.90                            5.79 × 10^-7^    -2.6                   0.0128               -3.5    0.0038

^a^Proportion of variance in gene expression due to mtDNA status in cultured cells and xenografts

^b^Bayes modified F test (multiple hypothesis corrected)

^c^Fold-change

^d^Benjamini and Hochberg corrected two-tailed Student\'s t-test

Gene expression profiling in mouse xenograft models
---------------------------------------------------

Animal care was in accordance with NIH and institutional guidelines. For the A549 xenograft model, 1.7 million A549 cells were injected subcutaneously/intramuscularly into the right hind flank of 6 week old CD-1 nude mice that had been irradiated with 4 Gy of total body irradiation from a ^137^Cs radiation source one day prior to tumor implantation \[[@B32]\]. For the A549 ρ^0^xenograft model, 1.5 million cells were used. Tumor and body weight measurements (6 or 7 mice per group) were performed three times per week once tumors became palpable. This occurred 41 versus 9 days post-implantation in ρ^0^and parental A549 xenograft models, respectively. Tumor volume was calculated using the equation V (mm^3^) = a × b^2^/2, where a is the largest diameter and b is the smallest diameter. No significant body weight loss was observed. To perform gene expression profiling, tumors (4 tumors per group) were harvested and snap frozen immediately on dry ice when the tumor size reached 500--800 mm^3^. Tumor tissue was dissected, homogenized in Trizol, and total RNA was isolated and subjected to gene expression analysis as described above.

Additional Files
----------------

Additional information about the data reported in this manuscript, including formatted gene expression data in these studies are available at *BMC Genomics*.

Results and discussion
======================

Establishment of A549 ρ^0^cell cultures
---------------------------------------

Candidate A549 ρ^0^lung cancer cell cultures were prepared using previously described ethidium bromide-based protocols \[[@B12]\]. Consistent with prior reports of ρ^0^cell lines (e.g. \[[@B7],[@B9],[@B33]\]), the resulting cells displayed auxotrophic growth dependence on pyruvate and uridine and elongated shape (data not shown). The growth rate of the candidate ρ^0^cells (27 hour generation time) was slower than the parental line (20 hour generation time) in pyruvate and uridine supplemented medium (Fig. [1A](#F1){ref-type="fig"}).

![**Characterization of cultured A549 and A549 ρ^0^cells**. (*A*) Growth rates of A549 and A549 ρ^0^cells in culture are provided. Experiments were run in triplicate with error bars representing ± 1 standard deviation. Doubling times obtained from the fitted curves (N = N~0~e^rt^) were 20.4 and 27.3 hours for parental A549 and A549 ρ^0^cultures, respectively. (*B*) The oxygen consumption of A549 and A549 ρ^0^cultured cells is provided. Where indicated, cells were treated with 1 μg/mL antimycin A, an inhibitor of the mitochondrial electron transport chain (ETC). Experiments were run in triplicate with error bars representing ± 1 standard deviation.](1471-2164-9-521-1){#F1}

We used the recently described pseudo-gene ratioing technique to estimate the amount of mtDNA remaining in the candidate A549 ρ^0^cell cultures (Methods) \[[@B21]\]. This technique is based on quantifying the relative co-amplification of a mtDNA sequence and a nuclear-embedded mitochondrial pseudogene (mtDNAψ) sequence \[[@B22]\] using total DNA extracted from candidate A549 ρ^0^cells and parental A549 cells. Assuming the mtDNAψ sequence is present in two copies per candidate A549 ρ^0^cell, we could estimate with 95% confidence that the candidate A549 ρ^0^cell cultures contained less than one copy of mtDNA per 14 cells. As a positive control, we used the same technique to estimate that a minimum of 45 mtDNA copies were extracted from each parental A549 cell (exact binomial upper 95% confidence limit). As a consequence of these observations, as well other biochemical characterizations described below, we will hereafter refer to the candidate A549 ρ^0^cell cultures as A549 ρ^0^cells.

Cultured A549 ρ^0^cells have impaired rates of oxygen consumption
-----------------------------------------------------------------

To characterize mitochondrial function in the parental A549 and A549 ρ^0^cells, we compared their rates of oxygen consumption. As expected, parental A549 cells showed robust oxygen consumption while the oxygen consumption of the A549 ρ^0^cells was indistinguishable (P = 0.41) from background (Fig. [1B](#F1){ref-type="fig"}). To demonstrate the involvement of respiration, we also treated parental A549 and A549 ρ^0^cells with antimycin A, an inhibitor of mitochondrial complex III of the electron transport chain (ETC) \[[@B34]\], prior to measuring oxygen consumption. As expected, antimycin A-treated A549 cells showed reduced oxygen consumption, while A549 ρ^0^cells were not significantly affected by drug-treatment (Fig. [1B](#F1){ref-type="fig"}). These results strongly suggest that residual mitochondria-dependent aerobic respiration in A549 ρ^0^cells, if present, is below the threshold that can be measured in this assay.

A549 ρ^0^cells grow in tumor xenografts at a slower rate than their parental cells
----------------------------------------------------------------------------------

Parental A549 cells and their ρ^0^derivatives both grew as xenografts when implanted shallowly (subcutaneously/intramuscularly) in the flank muscle of nude mice. mtDNA-depleted cell lines have been reported to form xenograft tumors \[[@B13],[@B18],[@B19]\]. Here, we found that A549 ρ^0^cells grow readily in xenograft, although at a slower rate and after a longer induction period (approximately 30 days) relative to the parental line (Fig. [2](#F2){ref-type="fig"}). This is consistent with the growth characteristics of tumor xenografts derived from N2B ρ^0^osteosarcoma \[[@B18]\], E3 ρ^0^serous ovarian carcinoma \[[@B18]\], HSA ρ^0^cervical cancer \[[@B18]\], and T47D ρ^0^breast cancer \[[@B19]\] cell lines relative to their parental counterparts.

![**Growth rates of A549 and A549 ρ^0^xenografts**. Median tumor volume over time in nude mice bearing tumors derived from A549 or A549 ρ^0^cells. Tumor volume measurements commenced at an initial average tumor volume of 155 mm^3^and 208 mm^3^, respectively. Experiments were conducted using six or seven mice per cohort with error bars representing ± 1 standard error of the mean (SEM).](1471-2164-9-521-2){#F2}

A549 ρ^0^cells do not express mtDNA-derived transcripts in culture or in xenografts
-----------------------------------------------------------------------------------

We performed quantitative PCR analysis of mtDNA-encoded *MT-ATP6*and *MT-CYB*transcripts in A549 and A549 ρ^0^cells grown in culture and in xenografts, in the absence of ethidium bromide. In contrast to the parental A549 cells, the expression of these two transcripts could not be detected in ρ^0^cells (Additional File [1](#S1){ref-type="supplementary-material"}). This strongly suggests that, in bulk, the A549 ρ^0^cells retained their mtDNA-depleted genotype over the course of their growth in culture and in xenograft. This was important to ascertain since it was possible that during their growth in xenograft, rare mtDNA-positive cells present in the injected A549 ρ^0^cell population could have substantially increased in abundance and affected our downstream analyses. Similarly, it is possible that A549 or A549 ρ^0^cells with certain genetic or epigenetic changes (e.g. those that confer a growth advantage) were selected for in culture or in xenografts and affected our results. This should be considered when interpreting the molecular analyses discussed below.

Gene expression profiling of cultured cells
-------------------------------------------

Gene expression profiles were generated in plateau phase A549 and A549 ρ^0^cells cultured in fresh medium supplemented with pyruvate and uridine prior to RNA isolation (see Additional File [2](#S2){ref-type="supplementary-material"} for all data and Additional File [3](#S3){ref-type="supplementary-material"} for volcano plot). All 276 transcripts that were differentially expressed (defined for every pair-wise comparison discussed hereafter as being \> 1.5-fold change, two-tailed Student\'s t-test *P*\< 0.01 (subjected to Benjamini and Hochberg correction for multiple comparisons), and \> 20 unit difference in geometric mean expression scores) are listed in Additional File [4](#S4){ref-type="supplementary-material"}. These include 131 transcripts that were more highly expressed in A549 ρ^0^cells and 145 that were more highly expressed in A549 cells.

Increased levels of EMT-related transcripts in cultured A549 ρ^0^cells
----------------------------------------------------------------------

To analyze differentially expressed genes in A549 cells and their mtDNA-depleted ρ^0^counterparts, we conducted Gene Ontology (GO) analyses on transcripts that were more highly expressed in the A549 ρ^0^cells than the parental cell line (see Additional File [5A](#S5){ref-type="supplementary-material"} for transcript names and Additional File [2](#S2){ref-type="supplementary-material"} for data analysis of specific transcript). We used stringent criteria (Fisher\'s exact test *P*\< 0.001 and at least 4 transcripts) for selection of enriched categories. The enriched categories included those related to cell adhesion (15 transcripts) and cell motility (4 transcripts). Upon further inspection of the transcripts in these categories, it became apparent that they reflect transcriptional signatures of the epithelial-mesenchymal transition (EMT), a developmental process by which stationary epithelial cells transform into mobile mesenchymal cells \[[@B35]\]. EMT can be driven by the activity of the transcription factor *SNAI2*, positively regulated by *LOXL2*\[[@B36]\], which leads to the over-expression of *CDH2*, *ITGB3*, and *VIM*. All five genes are over-expressed in the ρ^0^cells. The fact that *CDH1*and *FGA*are also less abundant in the ρ^0^cells further supports the hypothesis that the ρ^0^cells show an increasingly mesenchymal phenotype relative to their parental counterparts \[[@B35]\]. The above observations are consistent with prior reports of mtDNA-depleted A549 cells showing increased invasive behavior relative to parental A549 cells in a Matrigel basement membrane matrix invasion assay system \[[@B12]\].

Increased metal ion binding and glucuronidation gene expression in A549 ρ^0^cell cultures
-----------------------------------------------------------------------------------------

Two enriched GO categories were related to metal ion binding (*LOXL2*and metallothionein family members *MT1H*, *MT1G*, *MT1X*, and *MT2A*) and glucuronidation (including UDP glucuronosyltransferase 1 family members). The increased expression of MTF-1 regulated genes (i.e. metallothioneins) could indicate higher baseline levels of oxidative stress and/or free metals in the ρ^0^cells relative to their parental counterparts \[[@B25]\]. However, it is noteworthy that several oxidative stress response genes (e.g. *GPX2*, *GPX3*, and *GLRX*) are under-expressed in these ρ^0^cells. Glucuronidation is a cellular metabolic pathway in which UDP-glucuronosyltransferases (UGTs) convert lipophilic compounds, both endogenous and xenobiotic, into more readily excreted polar products. UGTs catalyze the transfer of the glucuronate moiety of uridine diphosphoglucuronate (UDPGA) to specific substrates, in order to attain this increased polarity. The observed differentially expressed UGT1A family members have different substrate specificities and collectively can react with a variety of endogenous lipophilic molecules, such as fatty acids and steroids \[[@B37]-[@B41]\]. Given that ρ^0^skin fibroblasts have impaired mitochondrial fatty acid β-oxidation \[[@B42]\], we propose that the increased abundance of glucuronidation-related transcripts in A549 ρ^0^cells is a survival mechanism to remove excess fatty acids that are normally metabolized to carbon dioxide and water in functional mitochondria.

Expression profiles of HIF-1 responsive transcripts in A549 ρ^0^cells
---------------------------------------------------------------------

Next, we focused on identifying key transcription factors that could account for a significant number of over-expressed transcripts in A549 ρ^0^cells. mtDNA-deficient cells have proven useful for dissecting the role that mitochondria play in HIF-mediated responses to oxygen levels (reviewed by \[[@B43]\]). In fact, increased baseline levels of HIF-1 activity in cultured ρ^0^cell lines have been noted by others \[[@B44],[@B45]\]. In our A549 ρ^0^cells, HIF-1 appeared to be an excellent candidate given the over-expression of two well-established downstream genes (*VEGFA*and *BNIP3*). We began our analyses by focusing on a group of 95 probe sets representing 63 unique HIF-1 responsive genes highlighted in a recent comprehensive review \[[@B46]\] (Additional File [6](#S6){ref-type="supplementary-material"}). While no other HIF-1 responsive genes reached our statistical criteria for over-expression, four other well-established HIF-1 regulated transcripts (*IGFBP1*, *IGFBP3*, *TF*, and *PTGS2*) were less abundant in the ρ^0^cells relative to their parental cells. This could reflect the influence of other transcription factors or accessory proteins that regulate HIF-1 activity.

The mechanism underlying the differential expression of HIF-regulated transcripts in mtDNA-deficient cells is unknown. For example, it has been proposed that a feedback loop involving mitochondrial enzymes and citric acid cycle intermediates leads to HIF-1 stabilization and tumorigenesis in several inherited forms of cancer caused by mtDNA mutations \[[@B47]\]. Another possible explanation might involve insulin-like growth factor signaling which has been shown to increase HIF-1 levels \[[@B48]\]. Importantly, the GO category insulin-like growth factor binding (*CYR61*, *HTRA1*aka *PRSS11*, *IGFBP4*, and *IGFBP7*) was enriched for transcripts that were more abundant in the ρ^0^relative to parental cells (Additional File [5A](#S5){ref-type="supplementary-material"}).

A549 ρ^0^cells over-express HIF-1 a protein relative to the parental cell line
------------------------------------------------------------------------------

To explore the mechanistic basis for the observed differential expression of HIF-responsive transcripts in culture, we measured the levels of HIF-1α protein in ρ^0^and parental cells by ELISA (Fig. [3A](#F3){ref-type="fig"}). The background levels of HIF-1α were found to be 3-fold higher in ρ^0^cells compared to the parental line. HIF-1α levels increased in the parental A549 line following treatment with cobalt acetate or incubation under hypoxic (1.5% O~2~) conditions. In A549 ρ^0^cells, HIF-1α levels were increased modestly following cobalt treatment but did not appear to be changed by hypoxic treatment. However, the level of HIF-1α protein does not solely determine its ability to induce gene expression, as post-transcriptional modifications are also known to modulate its activity \[[@B49]\].

![**Levels of HIF-1α and HIF-1 target proteins in A549 and A549 ρ^0^cells**. Plateau phase cultures were treated with control vehicle (mannitol), cobalt acetate (cobalt, 100 μM), or hypoxia (1.5% oxygen atmosphere). (*A*) Levels of HIF-1α protein relative to control vehicle after 4 hours treatment as measured by ELISA. Effect of incubation under hypoxic conditions or with cobalt acetate is shown for comparison. Error bars indicate one standard deviation. (*B*) Representative Western blot showing MT-CO2, PGK1, DDIT4, GLUT1, and HSP60 levels in A549 and A549 ρ^0^cells. PGK1 and DDIT4 levels were more abundant (1.4- and 4.0-fold, respectively) in A549 ρ^0^cells relative to A549 cells. In contrast, GLUT1 and HSP60 levels were only marginally changed (1.1- and 1.25-fold less abundant) in A549 ρ^0^cells relative to A549 cells. All estimates were made via phorphorimaging analysis with HSC70 levels serving as a loading control. Note that MT-CO2 levels could not be detected in any A549 ρ^0^experiment while DDIT4 was expressed at low levels, but could be quantified in normoxic cells.](1471-2164-9-521-3){#F3}

To further explore the possible functional consequences of HIF-1 over-expression, we measured the levels of several HIF-regulated gene products by Western blot (Fig. [3B](#F3){ref-type="fig"}). The MT-CO2 product was included in this analysis to demonstrate the absence of this mtDNA-encoded protein in A549 ρ^0^cells. In accordance with the expression data, we found that PGK1 and DDIT4 protein levels were increased in A549 ρ^0^cells (Fig. [3B](#F3){ref-type="fig"}). However, GLUT1 (aka SLC2A1) protein levels were essentially unchanged in A549 and A549 ρ^0^cells despite the fact that its transcript was 2.0-fold more abundant (corrected *P*= 0.017) in A549 ρ^0^cells. As could be expected, the incubation of either parental or ρ^0^cells in the presence of cobalt or under hypoxic conditions led to increased levels of these HIF-regulated proteins. The effect of cobalt was not as significant as that of hypoxia under these conditions. These data demonstrate that although baseline HIF-1 activity is higher in ρ^0^than parental cells, HIF-regulated activity can be induced further in both cases.

Decreased icosanoid metabolism and cytoskeleton gene expression in cultured A549 ρ^0^cells
------------------------------------------------------------------------------------------

In parallel, we conducted separate GO analyses on transcripts that were less abundant in A549 ρ^0^cells (*P*\< 0.001 and at least four probes sets) (Additional File [5B](#S5){ref-type="supplementary-material"}). The blood pressure regulation (*FGB*, *PTGS2*, *FGG*, and *FGA*) and icosanoid metabolism (*AKR1C2*, *PLA2G4A*, *PTGS2*, and *MGST2*) GO categories were significantly enriched for such transcripts. The presence of multiple fibrinogen family members in the former category could reflect possible differences in cell adhesion in ρ^0^cells. The icosanoid metabolism category could relate to the role arachidonic acid plays in the regulation of steroidogenesis and mitochondrial membrane permeability. It has been proposed that ATP generated by oxidative phosphorylation plays a key role in the generation and export of arachidonic acid from the mitochondria \[[@B50]\]. Through its role in leukotriene metabolism, arachidonic acid mediates the activity of steroidogenic acute regulatory protein (StAR), a key regulator of steroidogenesis. In addition, arachidonic acid can uncouple oxidative phosphorylation and alter mitochondrial membrane permeability \[[@B51]\].

The intermediate filament GO category was enriched for transcripts that were less abundant in ρ^0^cells (i.e. *KRT8*, *KRT19*, *NEFL*, *KRT18*, and *DSP*). *KRT18*plays a key role in maintaining the normal morphology of mitochondria \[[@B52]\]. Interestingly, *VIM*, another component of intermediate filaments shown to support mitochondrial morphology and organization \[[@B53]\], is over-expressed in ρ^0^cells. The dysregulation of intermediate filament genes in ρ^0^cells could contribute to their aberrant mitochondrial morphology and/or represent cellular responses to rescue mitochondrial organization.

Increased tRNA synthetase, MHC Class I, and lysosome gene expression in A549 ρ^0^xenografts
-------------------------------------------------------------------------------------------

Total RNA from A549 or A549 ρ^0^tumors (four per cohort) were also subject to gene expression profiling analysis (see Additional File [3](#S3){ref-type="supplementary-material"} for volcano plot). All 948 transcripts that were differentially expressed are listed in Additional File [7](#S7){ref-type="supplementary-material"}. These include 485 transcripts that were more highly expressed in the A549 ρ^0^tumors and 463 that were more highly expressed in A549 tumors. Three major functional categories emerged from GO analyses of over-expressed genes in ρ^0^xenografts (Additional File [8A](#S8){ref-type="supplementary-material"}). These categories were related to tRNA aminoacylation (composed of 9 tRNA synthetases), MHC class I (*B2M*, *MR1*, and six HLA gene family members), and the lysosome (23 transcripts).

The transcriptional induction of tRNA synthetases was previously highlighted in the analysis of cultured ρ^0^and parental lymphoblasts \[[@B44]\]. Recently, there is increased evidence that tRNA synthetases have functions additional to joining specific amino acids to their cognate tRNAs. These include the regulation of angiogenesis and inflammation \[[@B54],[@B55]\].

The over-expression of MHC Class I peptides is consistent with a report that MHC I is over-expressed in fibroblasts from patients with mtDNA defects as well as in cultured osteosarcoma ρ^0^cells relative to their parental counterparts \[[@B56]\]. In that study, IFN-γ treatment enhanced MHC1 over-expression in cultured osteosarcoma ρ^0^cells. Thus, the over-expression of interferon gamma receptor 1 (*INFGR1*) we observed in A549 ρ^0^xenografts (1.8-fold, corrected *P*= 0.004) could play a role in further stimulating MHC Class I peptide expression in these cells.

It has been proposed that MHC Class I over-expression in cells with mutated mitochondrial proteins provides a mechanism by which the immune system can recognize and eliminate defective cells \[[@B56]\]. Although ρ^0^cells do not have dysfunctional proteins encoded by mtDNA, the over-expression of MHC Class I genes may simply reflect a mechanism for marking cells with defective mitochondrial function.

The over-expression of lysosome genes could relate to their function in removing defective mitochondria within cells through autophagy \[[@B57]\]. This could complement the immune surveillance mediated removal of cells with defective mitochondria discussed above. We speculate that the over-expression of lysosome-related genes could reflect increased numbers of lysosomes and/or simply the increased functional activity of existing lysosomes.

A549 ρ^0^xenograft transcriptomes indicate decreased cell proliferation and glycolysis
--------------------------------------------------------------------------------------

Mitosis (21 transcripts) and spindle organization and biogenesis (9 transcripts) were two major functional categories showing enrichment for down-regulated transcripts in A549 ρ^0^xenografts (Additional File [8B](#S8){ref-type="supplementary-material"}). This would be expected given the lower proliferation rate of the A549 ρ^0^cells relative to their parental counterparts (Fig. [1A](#F1){ref-type="fig"}). The enrichment in the actin binding (21 transcripts) and cytoskeleton protein binding (27 transcripts) categories could also reflect differences in growth rates. Alternatively, they could relate to altered mitochondrial morphology, as discussed in our analysis of cultured ρ^0^cells.

Surprisingly, A549 ρ^0^xenografts showed decreased expression in the glycolysis category (nine transcripts). This would appear to be counter-intuitive given the fact that these xenografts do not express mtDNA-derived transcripts (Additional File [1](#S1){ref-type="supplementary-material"}) or MT-COX2 protein (Fig. [3B](#F3){ref-type="fig"}) and thus should have severely impaired oxidative phosphorylation. Indeed, the 4.7-fold increased abundance of *PCK2*in A549 ρ^0^cells could indicate higher levels of gluconeogenesis, consistent with prior reports in mtDNA-depleted A549 \[[@B12]\], 206B ρ^0^osteosarcoma \[[@B58]\], and ARPE19 ρ^0^retinal pigment epithelial \[[@B58]\] cultured cells. Apart from the aforementioned lower growth rate of ρ^0^xenografts, this probably reflects the general reduced abundance of HIF-regulated transcripts (*GAPDH*, *PKM2*, *ENO2*, *LDHA*, *EGLN1*, *SLC2A1*, *TF*, *P4HA1*, *IGF2*, *CA9*, *HIG2*, *ADM*, and *EGLN3*) as compared to the parental A549 xenografts (Additional File [6](#S6){ref-type="supplementary-material"}). This occurs despite the fact that HIF-1α is over-expressed (2.6-fold, *P*= 1.6 × 10^-4^) along with two other well-established HIF targets (*HK1*and *BHLHB3*). As discussed earlier, this is consistent with the post-translational control of HIF-1 α activity (protein modification or subunit localization) and/or the activity of other transcription factors.

Contribution of mtDNA to gene expression profiles of cultured cells and xenografts
----------------------------------------------------------------------------------

While gene expression differences between A549 cells grown in culture and in xenograft have been reported \[[@B59]\], comparison for both parental and mtDNA-deficient cells have not been previously performed. Interestingly, a greater number of transcripts were differentially expressed due to growth conditions (culture versus xenograft) than by mtDNA status. Importantly, infiltrating mouse cells have been demonstrated not to influence significantly gene expression profiles of tumor xenografts when using similar Affymetrix human microarrays \[[@B59]\]. All 2,512 transcripts that were differentially expressed in xenograft versus culture for the parental A549 line are listed in Additional File [9](#S9){ref-type="supplementary-material"}. The 2,108 differentially expressed transcripts for the A549 ρ^0^cells grown in xenograft versus culture are listed in Additional File [10](#S10){ref-type="supplementary-material"} (see Additional File [3](#S3){ref-type="supplementary-material"} for volcano plot). These results are borne out by hierarchical clustering analysis which first shows a clear separation of the gene expression profiles grown in culture versus xenograft and then separation according to mtDNA status, based on gene expression data obtained from 538 probe sets whose coefficient of variation was greater than 0.10 (Fig. [4](#F4){ref-type="fig"}).

![**Hierarchical clustering analysis of expression data from A549 and A549 ρ^0^cells in culture and in xenografts**. The dendrograms were generated based on average linkage hierarchical clustering of expression data from 538 probe sets whose coefficient of variation was greater than 0.10. Data from A549 cultures are provided in triplicate.](1471-2164-9-521-4){#F4}

We calculated the relative fraction of the variance associated with mtDNA status in the gene expression profiles from A549 ρ^0^and parental A549 cells grown in culture and in xenografts (Additional File [2](#S2){ref-type="supplementary-material"}). In particular, we focused on those transcripts for which over 50% of the variance (Benjamini and Hochberg corrected Bayes moderated F test *P*\< 0.01) could be explained by mtDNA status and where there was significant differential expression in any two of the pair-wise comparisons of A549 ρ^0^and parental A549 cells grown in culture or in xenograft. Overall, we discovered 430 transcripts (229 up-regulated and 201 down-regulated in A549 ρ^0^relative to the parental A549 cells) that met these criteria (Additional File [11](#S11){ref-type="supplementary-material"}). Table [1](#T1){ref-type="table"} provides a listing of a subset of these transcripts where at least 90% of the variance in gene expression was dependent upon mtDNA status.

Importantly, the probe set that was most strongly affected (in this case down-regulated) by mtDNA status measures the relative abundance of *MT-ND5*, the only mtDNA-encoded transcript represented in this microarray (Table [1](#T1){ref-type="table"}). *MT-ND5*is not expressed in the A549 ρ^0^cells in culture or in xenograft (i.e. ranking within the lowest 15^th^percentile of all median gene expression scores in both cases). This provided us with empirical proof that our sorting strategy was sensitive to detecting transcripts dependent upon mtDNA status. Overall, we found that the variance in the expression of transcripts within MHC-1 (6 transcripts) and glucuronidation (4 transcripts) GO categories are all highly dependent upon mtDNA status (Fig. [5](#F5){ref-type="fig"}). These transcripts were more abundant in A549 ρ^0^relative to the parental A549 cells. The MHC-1 and glucuronosyltransferase categories were previously discussed as having significance for the immune surveillance of cells with effective mitochondria and the detoxification of lipids that can accumulate due to defects in fatty acid metabolism. On the other hand, transcripts related to the protein complex assembly (11 transcripts) and chromatin (7 transcripts) GO categories were highly dependent upon mtDNA status and less abundant in A549 ρ^0^cells relative to the parental A549 cells (Additional File [12](#S12){ref-type="supplementary-material"}). This could reflect their slower growth rates relative to the parental cell line.

![**Gene Ontology analysis of up-regulated transcripts in ρ^0^cells whose variance is strongly influenced by mtDNA status**. The directed acyclic graph (DAG) represents the relationships of categories (shown in red) that are enriched for transcripts where mtDNA status accounted for over 50% of the observed variance in gene expression and are more abundant *in vitro*(i.e. cell culture) and/or *in vivo*(i.e. xenograft) in A549 ρ^0^cells relative to parental A549 cells. All 229 probe sets used in this analysis are provided in Additional File [11](#S11){ref-type="supplementary-material"}. The names of genes in terminal categories are provided the blue.](1471-2164-9-521-5){#F5}

In addition, mtDNA status affected multiple transcripts related to the above discussed epithelial-mesenchymal transition (EMT). Over 50% of the variance in the expression levels derived from probe sets for the previously described *SNAI2*, *ITGB3*, *CDH1*, and *FGA*genes could be explained by mtDNA status. The expression levels of all these genes indicated A549 ρ^0^cells have increased mesenchymal phenotypes relative to the parental A549 cells. However, the fold-changes in expression of these genes in ρ^0^versus parental cells were greater in culture than in the tumor xenografts (Additional File [2](#S2){ref-type="supplementary-material"}).

In contrast to genome-wide expression studies performed in yeast lacking mtDNA (ρ^0^petites), we observed no evidence for a strong dependence of the variance in peroxisomal gene expression (especially based on 26 probe sets for peroxin (*PEX*) genes responsible for peroxisome assembly) due to mtDNA status \[[@B60]\]. Nevertheless, this does not preclude mtDNA status affecting peroxisome function, through abundance and/or activity. For example, we observed that the mtDNA status had a significant effect on *PHYH*expression (explains 76% of the observed variance in expression, F-test *P*= 4.56 × 10^-4^). *PHYH*encodes a peroxisomal enzyme critical for the catabolism of phytanic acid, a branched chain fatty acid \[[@B61],[@B62]\]. *AMACR*, which also encodes an enzyme critical for phytanic acid metabolism, is also expressed higher in A549 ρ^0^xenografts relative to A549 xenografts (2.0-fold, corrected *P*= 0.007). Interestingly, AMACR, which localizes to both peroxisomes and mitochondria, is an emerging biomarker for prostate cancer \[[@B63]\]. Given reports of frequent mitochondrial defects in prostate cancer \[[@B64]\], it is tempting to speculate that the over-expression of AMACR in prostate cancer could be related to defective mitochondrial function. However, it should be emphasized that the mitochondrial defects in our mtDNA-depleted A549 system will be more severe than those found in human tumors.

mtDNA-dependent expression profiles show agreement with prior reports
---------------------------------------------------------------------

It can be questioned whether the observed mtDNA-dependent gene expression profiles are (i) shared amongst all cell lines, (ii) unique to our system, or (iii) reflect possible mutations in acquired in the nuclear genome of the ethidium bromide-treated A549 ρ^0^cells. To begin to address these issues, we searched for previous reports of differential gene expression in cultured ρ^0^cells relative to their parental cell lines. It is important to note that there is a limited literature on gene expression profiling in mtDNA-depleted cell cultures \[[@B16],[@B44],[@B65],[@B66]\] and that there are no previous reports of gene expression profiling in mtDNA-depleted xenografts. Nevertheless, we found confirmatory evidence for our observed major categories of mtDNA-dependent transcripts levels including: tRNA synthetases (over-expressed in osteosarcoma ρ^0^cells \[[@B66]\] and lymphoblastoid ρ^0^cells \[[@B44]\]), MHC-related transcript (over-expressed in osteosarcoma ρ^0^cells \[[@B56]\] and breast cancer ρ^0^cells \[[@B65]\]), UDP-glucuronosyltransferase (over-expressed in breast cancer ρ^0^cells \[[@B65]\]), and HIF1-α (over-expressed in lymphoblastoid ρ^0^cells \[[@B44]\]). Furthermore, the *FXY2D2*(aka *ATP1G1*) and the *VLDR*transcripts, whose levels were strongly dependent upon mtDNA-status and over-abundant in A549 ρ^0^cells (Table [1](#T1){ref-type="table"}), were found to be over-expressed in human fibroblasts with mutations in nuclear-encoded mitochondrial Complex I genes \[[@B67]\] and retinal pigment epithelial ρ^0^cells \[[@B14]\], respectively. Similarly, metallothionein transcripts were over-expressed in fibroblasts containing mutated nuclear-encoded mitochondrial genes, in agreement with our observations in A549 ρ^0^cell cultures \[[@B67]\]. Thus, results from multiple laboratories testing different ρ^0^cell cultures support the assertion that our current analyses at least partially reflect mtDNA-dependent gene expression relevant to multiple cell types. Future gene expression profiling experiments of mtDNA-depleted cells generated using non-chemical-based protocols, such as expressing siRNA against the *TFAM*gene \[[@B68]\] or a dominant negative form of the mitochondria-specific DNA polymerase-gamma \[[@B69]\], could provide valuable empirical data to assess our candidate mtDNA-dependent gene expression profiles. Ultimately, large-scale proteomic characterization of mtDNA-depleted and parental cells will be necessary to rigorously assess possible functional consequences of differential gene expression \[[@B15],[@B70]\].

Contribution of growth conditions to gene expression profiles
-------------------------------------------------------------

Next, we calculated the relative fraction of the variance associated with growth conditions in the gene expression profiles from ρ^0^and parental cells grown in culture and in xenografts. At first, we focused on those transcripts for which over 50% of the variance (corrected F test *P*\< 0.01) could be explained by growth conditions and where there was differential expression in any of the pair-wise comparisons of ρ^0^and parental A549 cells grown in culture or in xenograft. Overall, we uncovered 2,633 transcripts that met these criteria. In order to reduce transcript complexity, we focused on the subset of 551 transcripts (316 up-regulated and 235 down-regulated in xenografts relative to cultured cells) where growth conditions contributed to a robust 90% of the variance observed in the data set (Additional File [13](#S13){ref-type="supplementary-material"}). Table [2](#T2){ref-type="table"} lists a subset of these transcripts where at least 97% of the variance in gene expression was dependent upon mtDNA status.

###### 

Transcripts where 97% of the variance in gene expression is explained by growth conditions

                                                          Affymetrix Probe ID^a^   Gene Symbol   Entrez GeneID   Gene Description                              Growth Prop. of Variance^b^   F test^c^        ρ^0^Vivo/ρ^0^Vitro   WT Vivo/WT Vivo          
  ------------------------------------------------------- ------------------------ ------------- --------------- --------------------------------------------- ----------------------------- ---------------- -------------------- ----------------- ------ --------
  **Up-regulated and dependent on growth conditions**     211571_s\_at             *CSPG2*       1462            chondroitin sulfate proteoglycan 2            0.99                          1.41 × 10^-12^   34.6                 0.0001            19.0   0.0002
                                                          215646_s\_at             *CSPG2*       1462            chondroitin sulfate proteoglycan 2            0.99                          2.52 × 10^-12^   33.5                 0.0003            20.3   0.0003
                                                          220952_s\_at             *PLEKHA5*     54477           PI 3-phosphate-binding protein-2              0.99                          1.79 × 10^-11^   6.7                  0.0003            5.6    0.0006
                                                          209090_s\_at             *SH3GLB1*     51100           SH3-domain GRB2-like endophilin B1            0.99                          2.86 × 10^-10^   3.0                  0.0015            3.1    0.0002
                                                          216405_at                *LGALS1*      3956            lectin, galactoside-binding, soluble, 1       0.98                          6.43 × 10^-12^   11.5                 0.0007            14.4   0.0006
                                                          212254_s\_at             *DST*         667             dystonin                                      0.98                          3.64 × 10^-11^   3.9                  0.0006            4.7    0.0003
                                                          201056_at                *GOLGB1*      2804            golgin B1, golgi integral mem. protein        0.98                          2.12 × 10^-10^   3.3                  0.0008            2.9    0.0004
                                                          221829_s\_at             *TNPO1*       3842            transportin 1                                 0.98                          2.86 × 10^-10^   4.0                  0.0012            3.9    0.0005
                                                          204619_s\_at             *CSPG2*       1462            chondroitin sulfate proteoglycan 2            0.98                          3.01 × 10^-11^   12.2                 0.0003            7.5    0.0003
                                                          205173_x\_at             *CD58*        965             CD58 molecule                                 0.98                          1.70 × 10^-10^   3.5                  0.0014            3.7    0.0004
                                                          218901_at                *PLSCR4*      57088           phospholipid scramblase 4                     0.98                          1.32 × 10^-9^    3.5                  0.0009            3.8    0.0014
                                                          213229_at                *DICER1*      23405           Dicer1, Dcr-1 homolog                         0.97                          2.18 × 10^-10^   6.1                  0.0009            7.0    0.0013
                                                          208772_at                *ANKHD1*      404734          ankyrin repeat & KH domain containing 1       0.97                          1.97 × 10^-9^    2.5                  0.0027            2.4    0.0003
                                                          221731_x\_at             *CSPG2*       1462            chondroitin sulfate proteoglycan 2            0.97                          4.35 × 10^-11^   104.7                0.0001            30.9   0.0002
                                                          201057_s\_at             *GOLGB1*      2804            golgin B1, golgi integral mem. protein        0.97                          1.39 × 10^-9^    3.2                  0.0027            2.9    0.0002
                                                          214295_at                *KIAA0485*    57235           KIAA0485 protein                              0.97                          4.14 × 10^-10^   3.9                  0.0014            4.1    0.0008
                                                          201024_x\_at             *EIF5B*       9669            eukaryotic translation initiation factor 5B   0.97                          2.66 × 10^-9^    2.3                  0.0012            2.2    0.0012
                                                          201280_s\_at             *DAB2*        1601            disabled homolog 2                            0.97                          4.14 × 10^-10^   5.3                  0.0004            3.5    0.0006
                                                          218396_at                *VPS13C*      54832           vacuolar protein sorting 13 homolog C         0.97                          8.54 × 10^-10^   4.4                  0.0012            4.8    0.0006
                                                          205383_s\_at             *ZBTB20*      26137           zinc finger and BTB domain containing 20      0.97                          5.52 × 10^-10^   4.2                  0.0011            6.7    0.0003
                                                          219221_at                *ZBTB38*      253461          zinc finger and BTB domain containing 38      0.97                          2.98 × 10^-12^   6.0                  0.0007            6.5    0.0003
                                                          208663_s\_at             *TTC3*        7267            tetratricopeptide repeat domain 3             0.97                          1.19 × 10^-9^    3.1                  0.0021            3.1    0.0013
                                                          212070_at                *GPR56*       9289            G protein-coupled receptor 56                 0.97                          3.78 × 10^-10^   3.3                  0.0007            4.3    0.0008
                                                          203216_s\_at             *MYO6*        4646            myosin VI                                     0.97                          2.35 × 10^-9^    3.1                  0.0018            2.7    0.0012
                                                          204620_s\_at             *CSPG2*       1462            chondroitin sulfate proteoglycan 2            0.97                          6.97 × 10^-11^   104.5                0.0001            27.8   0.0002
                                                          212062_at                *ATP9A*       10079           ATPase, Class II, type 9A                     0.97                          2.73 × 10^-9^    2.5                  0.0002            2.7    0.0030
                                                          213775_x\_at             *ZNF638*      27332           zinc finger protein 638                       0.97                          2.86 × 10^-10^   2.6                  0.0008            3.0    0.0005
  **Down-regulated and dependent on growth conditions**   213201_s\_at             *TNNT1*       7138            troponin T type 1                             0.99                          6.43 × 10^-12^   -6.9                 0.0002            -5.0   0.0003
                                                          212432_at                *GRPEL1*      80273           GrpE-like 1, mitochondrial                    0.99                          1.37 × 10^-9^    -2.3                 0.0008            -2.3   0.0005
                                                          209507_at                *RPA3*        6119            replication protein A3, 14 kDa                0.98                          6.76 × 10^-10^   -2.2                 0.0010            -2.3   0.0002
                                                          209825_s\_at             *UCK2*        7371            uridine-cytidine kinase 2                     0.98                          1.09 × 10^-9^    -2.5                 0.0019            -2.3   0.0006
                                                          202533_s\_at             *DHFR*        1719            dihydrofolate reductase                       0.98                          3.51 × 10^-9^    -2.1                 0.0013            -2.0   0.0006
                                                          201577_at                *NME1*        4830            non-metastatic cells 1, protein expressed     0.97                          2.29 × 10^-9^    -2.1                 0.0014            -2.0   0.0004
                                                          208756_at                *EIF3S2*      8668            euk. transl. init. factor 3, subunit 2 beta   0.97                          1.92 × 10^-8^    -1.8                 0.0002            -1.7   0.0013
                                                          207239_s\_at             *PCTK1*       5127            PCTAIRE protein kinase 1                      0.97                          6.29 × 10^-9^    -1.9                 0.0017            -1.9   0.0007
                                                          204126_s\_at             *CDC45L*      8318            CDC45 cell division cycle 45-like             0.97                          2.31 × 10^-8^    -2.0                 0.0030            -1.9   0.0004
                                                          219162_s\_at             *MRPL11\**    65003           mitochondrial ribosomal protein L11           0.97                          1.37 × 10^-9^    -2.5                 0.0010            -2.2   0.0006
                                                          208847_s\_at             *ADH5*        128             alcohol dehydrogenase 5, chi polypeptide      0.97                          5.92 × 10^-8^    -1.7                 0.0022            -1.6   0.0007
                                                          210250_x\_at             *ADSL*        158             adenylosuccinate lyase                        0.97                          4.04 × 10^-9^    -2.0                 0.0015            -2.3   0.0012
                                                          208799_at                *PSMB5*       5693            proteasome beta 5 subunit                     0.97                          2.6 × 10^-8^     -1.9                 0.0025            -1.8   0.0004
                                                          221620_s\_at             *NOMO3*       408050          NODAL modulator 3                             0.97                          1.64 × 10^-9^    -2.0                 0.0015            -2.3   0.0004
                                                          210519_s\_at             *NQO1*        1728            NAD(P)H dehydrogenase, quinone 1              0.97                          7.60 × 10^-9^    -2.1                 0.0020            -1.8   0.0007
                                                          208910_s\_at             *C1QBP*       708             splicing factor SF2-associated protein        0.97                          1.63 × 10^-9^    -2.4                 0.0020            -2.5   0.0008
                                                          201903_at                *UQCRC1*      7384            ubiquinol-cytochrome c reductase              0.97                          9.25 × 10^-9^    -1.8                 0.0019            -2.1   0.0009
                                                          200039_s\_at             *PSMB2*       5690            proteasome subunit, beta type, 2              0.97                          5.72 × 10^-9^    -1.9                 0.0022            -2.0   0.0006
                                                          217960_s\_at             *TOMM22*      56993           mitochondrial import receptor Tom22           0.97                          1.04 × 10^-8^    -2.2                 0.0007            -1.9   0.0014
                                                          205691_at                *SYNGR3*      9143            synaptogyrin 3                                0.97                          1.83 × 10^-9^    -3.1                 0.0012            -2.4   0.0012

^a^Only probe tilings representing genes with annotated functions are provided

^b^Proportion of variance in gene expression due to growth conditions (i.e. cultured cells or xenografts)

^c^Bayes modified F test (multiple hypothesis corrected)

^d^Fold-change ^e^Benjamini and Hochberg corrected two-tailed Student\'s t-test

Of the GO categories enriched for transcripts whose expression was highly dependent upon growth conditions, only the nuclear RNA splicing GO category (9 transcripts) were more abundant in xenografts relative to cultured cells (Additional File [14A](#S14){ref-type="supplementary-material"}). However, multiple GO categories were enriched for transcripts whose variance was principally explained by growth conditions and were less abundant in xenografts relative to cell culture. These included categories related to mitochondrial function (50 mitochondrion transcripts), glycolysis (7 transcripts), electron carrier activity (11 transcripts), purine metabolism (5 transcripts), and the proteosome core complex (6 transcripts) (Additional File [14B](#S14){ref-type="supplementary-material"}).

The decrease in mitochondrial transcripts encoded by the nuclear genome may relate to the relative oxygen deprivation in xenografts relative to cell culture which would cause cells to rely less upon oxidative phosphorylation for their energy needs. The fact that growth conditions play a larger role in the expression of nuclear-encoded mitochondrial genes than the presence of the mitochondrial genome is not surprising if one considers the fact that ρ^0^cells form mitochondrial structures in the absence of mtDNA. Furthermore, this is consistent with observations that there are no differences in the expression of nuclear-encoded oxidative phosphorylation genes in parental and mtDNA-deficient osteosarcoma cells \[[@B71]\]. Interestingly, we could not detect differential transcript levels of nuclear encoded mtDNA polymerase (*POLG*), previously reported to be decreased on the protein level in HeLa ρ^0^cells \[[@B72]\], in any pair-wise comparison of experimental grouping performed in this study. However, we did find growth conditions accounted for 73% of the variance in gene expression (corrected F test *P*= 8.3 × 10^-6^and down-regulated in xenografts) of the nuclear encoded mitochondrial RNA polymerase *POLRMT*, which was reported to be down-regulated on the protein level in response to mtDNA depletion in HeLa cells \[[@B72]\].

The above observations, also supported by KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analyses of the same group of transcripts (Additional File [15](#S15){ref-type="supplementary-material"}), indicate that both glycolysis and aerobic respiration-related genes are less abundant in xenografts relative to culture. This could relate to the cells being cultured in glucose-rich medium that does not reflect the situation found *in vivo*. In combination, decreased glycolysis and oxidative phosphorylation in xenografts reflects lower energetic demands *in vivo*. Likewise, the decreased abundance of transcripts related to purine metabolism in xenografts is likely related to slower growth rates in xenografts relative to culture. Decreased purine metabolism could also reflect the absence of the super-physiological levels of glutamine present in cell culture media.

Role of mtDNA mutations in human disorders
------------------------------------------

A549 lung cancer cells provide an appealing model system to study mitochondrial function due to their ability to be grown in culture and in tumor xenografts. The potential role of mitochondrial function in cancer was first recognized by Otto Warburg when he observed that cancer cells show a characteristic shift in energy production from oxidative phosphorylation to glycolysis \[[@B73]\]. More recently, there has been increasing appreciation of the possible importance of inherited and somatic mtDNA mutations in cancer \[[@B74]\]. Based on the gene expression profiles observed in this study, ρ^0^xenograft tumor models could be of particular interest in determining mtDNA-mediated responses to specific cancer therapies, such anti-angiogenic agents.

In addition, ρ^0^cells play a critical role in the production of cybrid (cytoplasmic hybrid) cell lines containing specific mutations in mtDNA. While multiple groups have used this elegant system to study mitochondrial function in cultured cells (see reviews \[[@B4],[@B75]\]), only recently have these cybrids been used in tumor xenografts \[[@B64]\]. Gene expression profiling of such cybrids both in culture and in xenografts could provide valuable data to elucidate further the functional interactions between the nuclear and mitochondrial genomes.

Conclusion
==========

Although growth conditions had a greater influence on gene expression profiles than the presence of active mitochondria, we identified mtDNA-dependent gene expression profiles that are shared in cultured A549 cells and in xenografts. These profiles indicate that cells with mtDNA alterations have distinct biochemical properties that make them well-suited for elucidating responses to physiological perturbations, such as changes in oxygen and glucose levels, and testing the effects of specialized classes of chemotherapeutic agents. In addition, our studies suggest that gene expression profiling of mtDNA-depleted cells grown culture and in xenografts provide powerful means to investigate possible relationships between mitochondrial activity and gene expression profiles in normal and pathological cells.
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**Differentially expressed transcripts in A549 ρ^0^and A549 cells grown in culture.**Probe sets showing differential expression in cultured A549 ρ^0^and A549 cells are provided.
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**Gene Ontology analysis of transcripts that are differentially expressed in A549 ρ^0^cells relative to parental A549 cells in culture.** Functional categories of transcripts showing differential expression in cultured A549 ρ^0^and A549 cells are provided.

###### 

Click here for file

###### Additional file 6

**Analysis of HIF-1 responsive genes in A549 ρ^0^and A549 cells.** Gene expression profiles of HIF-1 responsive genes in A549 ρ^0^and A549 cells are provided.

###### 

Click here for file

###### Additional file 7

**Transcripts that are differentially expressed in A549 ρ^0^and A549 cells grown in xenografts.** Probe sets showing differential expression in A549 ρ^0^and A549 xenografts are provided.
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**Gene Ontology analysis of transcripts that are differentially expressed in A549 ρ^0^cells relative to parental A549 cells in xenografts.** Functional categories of transcripts showing differential expression in cultured A549 ρ^0^and A549 xenografts are provided.
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**Probe sets where 50% or more of the variance in gene expression profiles is influenced by mtDNA status.**Probe sets where 50% or more of the variance in gene expression profiles is influenced by mtDNA status are provided.
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###### Additional file 12

**Gene Ontology analysis of down-regulated transcripts in ρ^0^cells whose variance is strongly influenced by mtDNA status.**Functional categories of down-regulated transcripts in ρ^0^cells whose variance is strongly influenced by mtDNA status are provided.
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###### Additional file 13

**Probe sets where 90% or more of the variance in gene expression profiles is influenced by growth conditions.**Probe sets where 90% or more of the variance in gene expression profiles is influenced by growth conditions are provided.
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###### Additional file 14

**Gene Ontology analysis of transcripts whose variance are strongly dependent upon growth conditions.**Functional categories of transcripts whose variance are strongly dependent upon growth conditions are provided.
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###### Additional file 15

**KEGG analysis of differentially expressed genes in A549 ρ^0^and A549 cells.**Biological pathways containing differentially expressed genes in A549 ρ^0^and A549 cells are provided.
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